Buscar
Mostrando ítems 11-20 de 31
Oral antivirals for the prevention and treatment of SARS-CoV-2 infection
(AIDS Reviews, 2022)
Vaccines and antivirals are the classical weapons deployed to contain, prevent, and treat life-threatening
viral illnesses. Specifically, for SARS-CoV-2 infection, vaccines protect against severe COVID-19 disease
manifestations ...
Pre-Exposure Prophylaxis for viral infections other than HIV
(Infezioni in Medicina, 2022)
The battle against human viral infections has histori-cally relied on two medical strategies, namely vaccines to protect from contagion and antivirals to treat infected patients. In the absence of vaccines, antivirals have ...
Hepatitis C hospitalizations in Spain and impact of new curative antiviral therapies
(Journal of Viral Hepatitis, 2022)
Chronic hepatitis C virus (HCV) infection is major cause of decompensated cirrhosis and liver cancer. The advent of curative new antiviral therapies since year 2015 has dramatically improved the prognosis of HCV patients. ...
Liver cancer and hepatic decompensation events in patients hospitalized with viral hepatitis in Spain
(Hepatology International, 2022)
Background: Chronic viral hepatitis B, C, and D are the main causes of decompensated cirrhosis and liver cancer worldwide. Newborn HBV vaccination was implemented more than 2 decades ago in most EU countries. Furthermore, ...
Late presentation of human T-lymphotropic virus type 1 infection in Spain reflects suboptimal testing strategies: on behalf of the Human T-lymphotropic Virus (HTLV) Spanish Network
(International Journal of Infectious Diseases, 2022)
Objectives: Although only 10% of persons infected with human T-lymphotropic virus type 1 (HTLV-1) may develop virus-associated illnesses over their lifetime, missing the earlier diagnosis of asymptomatic carriers frequently ...
Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy
(Drug Design, Development and Therapy, 2023)
It has been ten years since the identification of NTCP as the cell surface receptor for HBV and HDV entry into hepatocytes. The search for molecules interfering with the binding of NTCP and HBV/HDV led to design bulevirtide ...
Is SARS-CoV-2 the only cause of long-COVID?
(AIDS Reviews, 2022)
Around 10% of adults infected with SARS-CoV-2 that survive a first episode of COVID-19 appear to experience long-term clinical manifestations. The signs and symptoms of this post-acute COVID-19 syndrome (PACS) include ...
Viral hepatitis in persons living with HIV in the post-COVID era
(AIDS reviews, 2023)
Coinfection with hepatitis viruses A to E is frequent in persons living with HIV (PLWH) and causes significant morbidity and mortality. Oro-fecal transmissible hepatitis A and E mostly produce acute self-limited episodes ...
The unexpected high prevalence of HBV subgenotype D4 in patients with chronic hepatitis B in Galicia, a northwestern Spanish region, reflects strong links with Latin America
(Journal of Clinical Virology, 2022)
Background: Hepatitis B virus (HBV) comprises 9 genotypes and multiple subgenotypes that depict differences in geographic distribution, clinical outcome and response to antiviral therapy. However, the molecular epidemiology ...
Impact of potent nucleos(t)ide therapy on hepatitis B hospitalisations in Spain
(Alimentary Pharmacology and Therapeutics, 2023)
Background: Chronic hepatitis B virus (HBV) infection is a major cause of decompensated cirrhosis and liver cancer worldwide. Newborn HBV vaccination was implemented in Spain two decades ago, and potent oral antivirals ...